CAJ | 학술논문

目前，全球范围内的肺癌发病率都趋升高。大多数非小细胞肺癌患者在就诊时已处于中、晚期，给治疗带来了巨大的挑战。以克唑替尼为代表的间变性淋巴瘤激酶酪氨酸激酶抑制剂对间变性淋巴瘤激酶基因融合变异阳性的晚期非小细胞肺癌患者的疗效及耐受性良好，表明基于间变性淋巴瘤激酶基因融合变异等分子标志物的肺癌分子靶向治疗模式已经在临床上得以建立和实际应用。
목전，전구범위내적폐암발병솔도추승고。대다수비소세포폐암환자재취진시이처우중、만기，급치료대래료거대적도전。이극서체니위대표적간변성림파류격매락안산격매억제제대간변성림파류격매기인융합변이양성적만기비소세포폐암환자적료효급내수성량호，표명기우간변성림파류격매기인융합변이등분자표지물적폐암분자파향치료모식이경재림상상득이건립화실제응용。
The incidence of lung cancer has significantly increased worldwide at present. Most of the patients with non-small cell lung cancer (NSCLC) are in the advanced stage when diagnosed, which brings a huge challenge to the therapeutic strategy of NSCLC. Anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKI) represented by crizotinib have showed good efficacy and tolerability in clinical practice. With the aim of overcoming crizotinib-acquired resistance, different second generation of ALK-TKIs have been recently evaluated and demonstrated fine research results according to several clinical trials. Molecular targeting and individualized treatment mode based on the molecular markers of the ALK fusion gene mutation of lung cancer has been established and applied in clinical practice.